Designed and manufactured specifically for pharmaceutical capsule filling

Similar documents
STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System

Table 1. Coating Parameters

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy

STARCH Application Data

Direct Compression Formulation Using Starch 1500 with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry II (85F Series)

Narrowing the gap between clinical capsule formulations and commercial film-coated tablets

Lactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets

The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices

Protection and Processing of a Highly Hygroscopic Herbal Extract by Drug Layering and Film Coating

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation

The unlocked synergy of DFE Pharma MCC

Opadry Enteric. Application Data. Drug Release from Acrylic-Based Opadry Enteric (94 Series) Coated Tablets INTRODUCTION MATERIALS AND METHODS

Technical brochure StarLac

Comparative Evaluation of Enteric Film Coatings Applied in Organic Solvents

Co-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009

Excipient Considerations for Continuous Manufacturing Implementation

ORAL DOSAGE OVERVIEW

The binding performance of DFE Pharma Starch

The solid choice for Omega-3

Technical brochure CombiLac

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process

LYCOAT. New solutions for Film Coating from Roquette. LYCOAT for quicker quality coating

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

Easy, fast and reliable!

YOUR ORAL SOLID DOSE. In pursuit of excipient excellence

CONSIDERATION OF THE END USER AND THE LIMITATIONS DURING THE ORAL ADMINISTRATION DRUG DESIGN: CHALLENGE IN DIFFERENT AGE GROUPS

USP Chewable Gels Monographs

Tablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good

The Wright Grou. the history of

SCIENTIFIC DISCUSSION. AkuriT-3 Tablets*

OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

SCIENTIFIC DISCUSSION

Abacavir (as sulfate) 300 mg tablets WHOPAR part 6 May 2016 (Hetero Labs Ltd), HA575

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies

Pharmaceutical Studies on Formulation and Evaluation of Sustained Release Tablets Containing Certain Drugs

Adopting Technologies to Enhance Quality in Manufacturing

SPS Pharma: Who we are?

CHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION

SCIENTIFIC DISCUSSION

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

SUMMARY AND CONCLUSION

SCIENTIFIC DISCUSSION

DRUG PRODUCT PERFORMANCE: CONSIDERATIONS FOR INTERCHANGEABILITY OF MULTISOURCE DRUG SUBSTANCES AND DRUG PRODUCTS

Introduction. Nwoko Valentine E

Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose

Wettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants?

SCIENTIFIC DISCUSSION

innovative products. faster to market. reliably supplied.

CHEWABLE SOFTGEL TECHNOLOGY

Folic Acid in Human Nutrition

FLORITER. New Technology for Innovative Formulation Design.

SCIENTIFIC DISCUSSION. Efavirenz

REGULATORY PERSPECTIVE. Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore

A matter of timing. ensure optimal delivery for acid-sensitive products. capsugel.com

3. Drug or plant or excipients profile

Indulgent Coconut Milk Yogurt through Functional Tapioca Starch. Food Innovation Center SMS CORPORATION THAILAND 15 Nov, 2017

Formulation and Evaluation

Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products

A Stronger Start to Every Workout

Easy, fast and reliable!

Int. Res J Pharm. App Sci., 2014; 4(1):47-51 ISSN:

EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER. Life-saving pharmaceuticals start with high-quality ingredients

Differentiate your brand. with the unique look and performance of capsugel s press-fit and xpress-fit gelcaps. capsugel.com

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use

SCIENTIFIC DISCUSSION

905 UNIFORMITY OF DOSAGE UNITS

African Journal of Pharmaceutical Research & Development

SCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).

CHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION

Formulation and Development of Sustained Release Tablets of Valsartan Sodium

Kollicoat Smartseal 30 D Active Protection

SCIENTIFIC DISCUSSION

Dow Wolff Cellulosics. Using ingenuity and savvy. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

innovative products. faster to market. reliably supplied.

Journal of Chemical and Pharmaceutical Research

Typical Opadry II coating conditions with a product bed temperature of around o C were found to be suitable

Food supplement manufacture

EVALUATION OF EFFERVESCENT FLOATING TABLETS. 6.7 Mathematical model fitting of obtained drug release data

Journal of Pharmaceutical and Scientific Innovation

Technical Transfer- A tablet process transfer case study. Presented by Jonathan King 4 July, 2016

Commercial Bulleting Aloe Flakes

Content Uniformity of Direct Compression tablets

FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels

Innovations in Design: NIA-West. Missy Lowery, MSc Head of Integrated Marketing Capsugel, now a Lonza company 11/13/2017

Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media

Journal of Chemical and Pharmaceutical Research, 2017, 9(6): Research Article

LAB.2. Tablet Production Methods

WE VE GOT THE POWDER THE KEY TO YOUR NEW MEDICATED CHEWING GUM

Excipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical

PREPARATION AND INVITRO EVALUATION OF RABEPRAZOLE SODIUM DELAYED RELEASE ENTERIC COATED TABLETS

Evaluation of different binders for roller compaction R. Wang, W. Liu, T. Durig

Dextrol and Strodex Surfactant Selection Guide

7. SUMMARY, CONCLUSION AND RECOMMENDATIONS

Partner with the Global Leader in Drug Delivery Systems

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use

Soluplus The Solid Solution Opening New Doors in Solubilization.

ANIMAL HEALTH DIVISION. Technologies & Services

Transcription:

EXCIPIENTS Designed and manufactured specifically for pharmaceutical capsule filling Simple formulation Superior flow and weight uniformity Clean and efficient processing This document is valid at the time of distribution. Distributed -Ago-218 (UTC)

Uniquely Colorcon StarCap, co-processed starch excipient, simplifies formulation and improves processing of your capsule dosage form. With high flow and low adhesion, StarCap results in clean and efficient capsule filling operation. StarCap provides diluent and disintegrant functionality, reliable ph-independent dissolution, and aids long-term stability of reactive drugs. Designed Specifically for Pharmaceutical Use Manufactured in dedicated cgmp facilities, StarCap is a globally acceptable co-processed specialty excipient, comprising native and partially pregelatinized maize starch. Commonly used in capsule filling for its fast disintegration, native starch has inherently poor flow. By co-processing native starch with pregelatinized starch to create StarCap, the result is a free-flowing powder with excellent disintegration and compressibility for plug formation. The Natural Choice StarCap is 1% vegetable-derived and sourced from non-gmo corn, overcoming concerns associated with lactose and other milk derivatives, such as intolerance and BSE/ TSE issues. μm μm Native Starch (-1 µm) Native Starch Fast disintegration Poor flow Sticky on contact StarCap (average 9 µm) Partially pregelatinized starch Binding power Disintegrant compressibility Co-Process StarCap Free flowing Excellent compressibility for plug formation Low adhesion Fast disintegration This document is valid at the time of distribution. Distributed -Ago-218 (UTC)

Weight Consistency in High Speed Encapsulation Ensuring weight uniformity and enhancing powder flow are essential to effective capsule filling1. StarCap demonstrates smooth operation on high-speed production scale, continuous movement, dosator encapsulation equipment at 1, capsules per hour. In a case study, capsules were filled with StarCap, and weight measurements taken every minute, for 3 minutes. Low weight variation demonstrates that StarCap is highly applicable for high-speed capsule filling operations. 392 mg Max Fill 38 mg Target Fill 363 mg Min Fill RSD = 1.2% Reliable Dissolution ph Independent StarCap achieves rapid disintegration and ph-independent drug release profiles. Using a model drug, propranolol hydrochloride, both capsule disintegration and drug release were shown to be equivalent in high and low ph media. Capsule Dissolution: Gelatin Capsules filled with 2% Propranolol HCL / 8% StarCap Size 1 Gelatin Capsule Disintegration Time (n=6) 2% Propranolol HCl / 8% StarCap 1 Drug Released (%) Disintegration Time (minutes) 2 1. 1. 8 6 4 ph6.8 buffer 2.1 N HCI ph 6.8.1N HCl 1 2 Time (minutes) 1. F. Muzzio, S. Stevemann, M. Richardson, J. Davidson, Capsule Manufacturing: Improving performance in product development and production, Pharmaceutical Processing, March 213. This document is valid at the time of distribution. Distributed -Ago-218 (UTC) 3

Dependable Stability The inert nature of StarCap also improves stability of propranolol hydrochloride, as a model drug, and brings formulation simplification with less chance of drug/excipient interaction. Size Capsules with % Propanolol HCl + 7% StarCap or Lactose. Stability @ 4 C / 7% RH 1 Drug Released (%) After six months storage at accelerated stability conditions (4 C/7% RH) drug release from the capsule formulation with StarCap remained unchanged. However, the lactose-based formulation exhibited a measurable slowdown in release after 3 and 6 months. The inherent non-reactivity of StarCap contributes to maintaining dissolution profiles over time, resulting in dependable stability. 8 6 Initial - StarCap 3 mo - StarCap 6 mo - StarCap Initial - Lactose 3 mo - Lactose 6 mo - Lactose 4 2 1 Time (minutes) 2 The natural choice for capsule applications - StarCap provides simple formulation, superior flow and weight uniformity, and efficient processing. From Core to Coating naturally Your Supplier of Choice This document is valid at the time of distribution. Distributed -Ago-218 (UTC) 3

Formulation Simplification StarCap replaces capsule filling excipient combinations, reducing formulation complexity without impacting drug release. Fewer ingredients lessen potential for interactions with the drug and reduce raw material testing and inventory. In a case study, a commercially marketed gabapentin capsule was reformulated with StarCap, replacing a blend of lactose, native starch, and talc. Gabapentin The simplified StarCap formulation meets USP monograph specifications for drug assay, fill weight variation, and drug dissolution. Gabapentin Assay USP Monograph Specification StarCap Formulation 1 8. 11.% 99.2 13.3% 8 Content Uniformity Relative Standard Deviation (RSD) NMT 6.% 1.3% Capsule Fill Weight Variation 9 11% 98.2-16.9% Gabapentin StarCap MgSt Gabapentin Innovator Capsule 6 Gabapentin +StarCap 4 2 NLT 8% in 3 min Gabapentin Dissolution Avg. % Drug Released Property Size gelatin capsules using a tamp filling machine at 3 capsules/hr. Lactose Starch Talc MgSt >8% in min 1 2 Time (min) 3 3 Superior Flow and Compressibility for Process Efficiency 3 Flow Rate (g/sec) 3.2 3 Carr s Index (%) 24.7 2.6 2.6 2 8. 1 3.6 Higher powder flow rate and lower Carr s compressibility index are desirable for capsule weight consistency and clean filling operations. Compared to other commonly used capsule filling ingredients, StarCap combines superior flow and compressibility resulting in minimal dusting and low adhesion to contact surfaces..6 Native Starch MCC 9 micron Spray-Dried Lactose StarCap *Flow rate measured using Sotax FT 3 Flowability Tester, vibration setting 1.7g From Core to Coating naturally Your Supplier of Choice This document is valid at the time of distribution. Distributed -Ago-218 (UTC)

Deliver High Performance Products - with Colorcon Choose Colorcon, leader in pharmaceutical solid oral dose solutions, as a formulation partner of choice in every phase of your product development. Film Coatings: Optimized formulations specifically for your application and regulatory needs including customized colors and color matching Innovative products for mechanical integrity, gloss, pearlesence and environmental protection Tablet design concepts, consulting and services to build a strong brand image and stand out from the competition. Formulation Technologies: Full range of functional excipients Technologies for development and production of delayed/enteric release and extended/controlled release tablets and multiparticulates HyperStart service and extensive applications data to provide starting formulations to save you development time and money Extensive formulation know-how and technical support to achieve the exact drug release profile desired. Contact your Colorcon representative or call: North America +1-2-699-7733 Europe/Middle East/Africa +44-()-1322-293 Latin America +4-11-6-77 India +91-832-6727373 You can also visit our website at www.colorcon.com China +86-21-619823 BPSI Holdings LLC, 216. The information contained in this document is a proprietary to Colorcon, Inc. and may not be used or dissminated inappropriately All trademarks, except where noted are property of BPSI Holdings LLC. The information contained in this document is not intended as legal advice, and should not be relied upon for that purpose. pib_stcap_v1_1.216 Powered by TCPDF (www.tcpdf.org) This document is valid at the time of distribution. Distributed -Ago-218 (UTC)